Full-Time

Quality Assurance Specialist

Posted on 11/23/2025

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Cardiff, UK

In Person

Category
QA & Testing (1)
Required Skills
Data Analysis
Requirements
  • Educated to degree level or equivalent in a science or QA-related discipline
  • Experience in an operational quality environment
  • GMP Skill Level 1 (desirable)
  • Strong written, verbal, and listening communication skills
  • High attention to detail and analytical ability
  • Basic to intermediate IT competence
  • Customer-focused, conscientious, and self-motivated
  • Able to lead by example and achieve results through cooperation and influence
  • Ideally a member of a professional body recognised by the UK MHRA
  • Please note that candidates with a lower-level qualification but significant QA pharma industry experience will also be considered
Responsibilities
  • Provide quality oversight of Manufacturing, Primary and Secondary Packaging, and Clinical Labelling operations
  • Identify and assess quality risks during routine operations, with the authority to stop production where required
  • Investigate quality issues, provide resolution, and approve the restart of production lines
  • Make decisions on product suitability for use, rejection, and progression to QP certification
  • Support Quality Management to ensure compliance with GMP standards, company policies, and regulatory requirements across the Tredegar and Oakdale sites
  • Collaborate closely with Manufacturing and Packaging teams to provide QA guidance and resolve quality issues
  • Interpret and apply GMP regulations (MHRA/EU/FDA) to all manufacturing and packaging activities, including development, clinical, commercial, and unlicensed products
  • Evaluate complex quality data, making professional decisions to ensure compliance while meeting business deadlines
  • Influence and advise stakeholders at all levels, up to director level, on quality matters and conflict resolution
  • Ensure quality is built into facilities, processes, and products, and liaise with clients as needed
  • Lead and manage team members (if applicable), ensuring KPIs, targets, and deadlines are met
  • Uphold high ethical standards in line with stringent pharmaceutical regulatory requirements
  • Ensure adherence to SOPs, working practices, and entry requirements across all manufacturing and packaging areas

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • San Diego’s 2028 line more than doubles RTU syringe and cartridge capacity.
  • Bedford’s line reaches 33 million annual vial units, strengthening sterile supply.
  • Autoinjector capacity exceeds 250 million units annually after the 2027 line.

What critics are saying

  • San Diego capacity arrives only in first-half 2028, leaving competitors more immediate supply.
  • Large sterile buildouts create execution risk from validation, yield, and regulatory delays.
  • Customer concentration can strand expensive capacity if programs are delayed or cancelled.

What makes PCI Pharma Services unique

  • PCI combines sterile fill-finish, device assembly, packaging, and cold-chain support.
  • San Diego and Bedford add specialized capacity for prefilled syringes, vials, and lyophilization.
  • Phased U.S. and European investments target clinical-through-commercial drug-device programs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at PCI Pharma Services who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.

INACTIVE